Targeted treatment for advanced cancers using antibody-based therapies
Spatially precise radio-chemo-immunotherapy using antibody conjugates
This study is testing a new way to treat locally advanced cancers by using special drugs that target cancer cells directly, combined with traditional chemotherapy and radiation, to help improve treatment results and reduce side effects for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11001443 on NIH RePORTER |
What this research studies
This research focuses on improving treatment for locally advanced cancers by combining targeted therapies with traditional chemotherapy and radiotherapy. It utilizes antibody-drug conjugates (ADCs) that specifically target tumor cells, allowing for the delivery of potent drugs directly to the cancer while minimizing damage to healthy tissues. The approach aims to enhance the immune response against tumors and improve overall treatment outcomes. By using advanced drug delivery systems, the research seeks to optimize the effectiveness of existing cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with locally advanced cancers who have not responded adequately to standard treatments.
Not a fit: Patients with early-stage cancers or those whose tumors do not express the targeted receptors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less harmful treatments for patients with advanced cancers.
How similar studies have performed: Previous research has shown promise in using targeted therapies and antibody-drug conjugates for cancer treatment, indicating a potential for success with this approach.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Advani, Sunil J — University of California, San Diego
- Study coordinator: Advani, Sunil J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.